Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Danuglipron in T2DM with Renal Impairment
NCT04616027Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jan 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of danuglipron in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time and 2 more. Started Jan 2021; status: completed.
02
Drugs
danuglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04616027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04616027.